

6. (Thrice Amended) An isolated polypeptide according to Claim 3 wherein said derivative comprises a dimer of the fragment selected from the group consisting of:

- E1  
Cont  
Sub  
G1  
Cont
- (a) amino acids 848-1278 of a type F botulinum toxin (SEQ ID NO:1),
  - (b) amino acids 848-991 of a type F botulinum toxin (SEQ ID NO:2),
  - (c) amino acids 992-1135 of a type F botulinum toxin (SEQ ID NO:3), and
  - (d) amino acids 1136-1278 of a type F botulinum toxin (SEQ ID NO:4).

11. (Amended) A polypeptide according to Claim 8 comprising a fusion protein

of: -

- E2  
Sub H6  
with
- (a) amino acids 848 to 1278 of a type F botulinum neurotoxin (SEQ ID NO:1),
  - (b) a purification moiety.

E3  
Sub G9

28. (Amended) The fusion protein of claim 27 wherein said *C. botulinum* amino acid sequence consists of the contiguous amino acid sequence of amino acids 848 to 1278 of said *C. botulinum* neurotoxin (SEQ ID NO:1).

E4  
Sub G10

30. (Amended) The fusion protein of claim 27 wherein said *C. botulinum* neurotoxin amino acid sequence comprises at least one amino acid sequence selected from the contiguous amino acid sequence of amino acids 848-991 of said *C. botulinum* neurotoxin (SEQ ID NO:2), the contiguous amino acid sequence of amino acids 992-